The following is a summary of “Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: ...

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

Autologous hematopoietic stem cell transplantation did not improve outcomes for patients with mantle cell lymphoma and undetectable minimal residual disease.

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

The Consumer Electronics Show (CES) kicked off in Las Vegas, bringing together a myriad of innovative technologies from ...